The BioCircular Materials Alliance initiated by Spiber welcomes new partners including Stella McCartney and publishes its first Progress Report

The BioCircular Materials Alliance initiated by Spiber welcomes new partners including Stella McCartney and publishes its first Progress Report

Stella McCartney, Marzotto Wool Manufacturing Srl, Fashion for Good, and 13 new companies and organizations have joined the BioCircular Materials Alliance (the "Alliance"), led by biomaterials pioneer Spiber. The Alliance published its first...

Wonderful Indonesia Co-Branding: A Kaleidoscope of Achievements in 2024

Wonderful Indonesia Co-Branding: A Kaleidoscope of Achievements in 2024

JAKARTA, Indonesia, Dec. 30, 2024 /PRNewswire/ -- The Ministry of Tourism and Creative Economy has highlighted key achievements from its Wonderful Indonesia Co-Branding partnership in 2024. The program has effectively strengthened the Wonderful...

Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

Microtech Announces First Human Case of Implantable Microsensor for Heart Failure

TEL AVIV, Israel, Dec. 26, 2024 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol Inc., a leader in global MedTech research and development, announced that it has initiated human clinical trials of their microsensor platform, in a...

TPIsoftware Launches GreenSwift in Vietnam with Pilot Project Initiated to Drive ESG Transformation

TPIsoftware Launches GreenSwift in Vietnam with Pilot Project Initiated to Drive ESG Transformation

TAIPEI, Dec. 26, 2024 /PRNewswire/ -- TPIsoftware (TWSE: 7781) and Vietnam's key partners have signed an MOU to deepen collaboration in promoting a more sustainable, decarbonized future. The signing took place in Hanoi, Vietnam, on December 26,...

Designing for the future: SM's vision through an architect's lens

Designing for the future: SM's vision through an architect's lens

PASAY CITY, Philippines, Dec. 23, 2024 /PRNewswire/ -- The SM Group, through its integrated property developer arm, SM Prime Holdings, Inc., is setting a benchmark in sustainable and disaster-resilient design. Embracing innovation, the company...

China Matters' Feature: Guarding the "Snow Mountain Genies": For the Long-term Habitat of the Yunnan Snub-nosed Monkey

China Matters' Feature: Guarding the "Snow Mountain Genies": For the Long-term Habitat of the Yunnan Snub-nosed Monkey

SHANGRI-LA, China, Dec. 20, 2024 /PRNewswire/ -- The Yunnan snub-nosed monkey, a rare and endangered primate species unique to China, is found only in the high-altitude areas at the junction of Yunnan and Xizang. This specific requirement for their...

Chinese and Latin American youths rise to global poverty challenge through Tsinghua's initiative

Chinese and Latin American youths rise to global poverty challenge through Tsinghua's initiative

BEIJING, Dec. 17, 2024 /PRNewswire/ -- This is a report from China.org.cn: When Tsinghua University initiated the China-Latin America 2024 Youth Challenge to Alleviate Poverty, inviting students to develop innovative and practical solutions to...

Global Times: BWF secretary-general stresses safer courts, China's 'powerhouse' role in exclusive interview

Global Times: BWF secretary-general stresses safer courts, China's 'powerhouse' role in exclusive interview

BEIJING, Dec. 17, 2024 /PRNewswire/ -- The Badminton World Federation (BWF) has encountered issues this year over how to best maintain players' health and well-being on the court. Thomas Lund, BWF secretary-general, exhibited a proactive attitude...

Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101

Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101

Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China AC-101 demonstrated a favorable safety and PK/PD...

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™

GNT Pharma Reports Significant Improvements in Stroke Patients Treated with its pioneering Phase 3 Drug Nelonemdaz™

** IND submitted to the FDA showing significantly improved patient condition when administered within 70 minutes of arrival at the Emergency Room ** *Multinational Phase 3 Clinical Trial protocols confirmed and initiated with leading global stroke...

  • 1
  • 2
  • menu
    menu